256443-86-4

Upstream product

• 6346-05-0 3-benzyloxy-4-methoxybenzaldehyde 
• 228869-37-2 3-Benzyloxy-N,N-diethyl-2-formyl-4-methoxy-benzamide 
• 228869-36-1 3-benzyloxy-N,N-diethyl-4-methoxy-benzamide 
• 228869-38-3 3,4-dihydroxy-5-methoxy-3H-isobenzofuran-1-one 
• 228869-39-4 5-hydroxy-6-methoxy-2H-phthalazin-1-one 
• 41222-60-0 3-benzyloxy-4-methoxybenzoyl chloride 
• 58452-00-9 3-benzyloxy-4-methoxybenzoic acid 
• 1823-14-9 5-phenyl-1-pentyne 
• 256443-83-1 trifluoro-methanesulfonic acid 6-methoxy-1-oxo-1,2-dihydro-phthalazin-5-yl ester 

Downstream Products

• 256443-15-9 1-(3,5-dichloro-pyridin-4-ylmethyl)-6-methoxy-5-(5-phenyl-pent-1-ynyl)-phthalazine 
• 256443-87-5 1-Chloro-6-methoxy-5-(5-phenyl-pent-1-ynyl)-phthalazine 

Relevant academic research and scientific papers

Phthalazine derivatives phosphodiesterase 4 inhibitors

The present invention provides a compound selected from the group including: 1-(3,5-dichloro-pyridin-4-ylmethyl)-6-methoxy-4-phenyl-phthalazine; 4-(3,5-dichloro-pyridin-4-ylmethyl)-7-methoxy-1H-phthalazin-2-carboxylic acid methyl ester; benzyl-{3-{1-(3,5-dichloro-pyridin-4-ylmethyl)-6-methoxy-phthalazin-5-yl}-prop-2-ynyl}-methyl-amine; 1-(3,5-dichloro-pyridin-4-ylmethyl)-6-methoxy-5-(5-morpholin-4-yl-pent-1-ynyl)-phthalazine dihydrochloride; 3-{1-(3,5-dichloro-pyridin-4-ylmethyl)-6-methoxy-phthalazin-5-yl}-prop-2-yn-1-ol; 1-(3,5-dichloro-pyridin-4-ylmethyl)-6-methoxy-4-morpholin-4-yl-phthalazine; 1-(3,5-dichloro-pyridin-4-ylmethyl)-6-methoxy-4-(1,2,4)triazol-1-yl-phthalazine; N→O derivatives thereof; and pharmaceutically acceptable salts thereof. The invention also provides a pharmaceutical composition which includes a therapeutically effective amount of the above compound in admixture with a suitable carrier.

The synthesis and biological evaluation of a novel series of phthalazine PDE4 inhibitors I

This communication describes the synthesis and in vitro evaluation of a novel and potent series of phosphodiesterase type IV (PDE4) inhibitors. The compounds described represent conformationally constrained analogues of RP 73401, Piclamilast. Preliminary evidences of reduced side effects of 11 compared to standards are also reported. (C) 2000 Elsevier Science Ltd.